Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus-related hepatocellular carcinoma
Article first published online: 18 JAN 2012
© 2012 The Japan Society of Hepatology
Volume 42, Issue 6, pages 564–573, June 2012
How to Cite
Sakae, M., Kubo, S., Takemura, S., Sakata, C., Uenishi, T., Kodai, S., Shinkawa, H., Urata, Y., Ohata, K., Kaneda, K., Nishioka, T., Nozawa, A. and Suehiro, S. (2012), Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Hepatology Research, 42: 564–573. doi: 10.1111/j.1872-034X.2011.00959.x
- Issue published online: 8 MAY 2012
- Article first published online: 18 JAN 2012
- Received 4 September 2011; revision 12 November 2011; accepted 4 December 2011.
- cancer recurrence;
- hepatocellular carcinoma;
- hepatitis C virus;
- second hepatic resection;
- sustained virological response
Aim: Several investigators have shown that interferon (IFN) therapy can suppress the recurrence of hepatocellular carcinoma (HCC) after curative treatment. We investigated the effect of IFN therapy on the first and second HCC recurrence following hepatic resection of hepatitis C virus (HCV)-related HCC.
Methods: Subjects included 166 patients who had undergone curative resection for a single HCV-related HCC. We analyzed the outcome after initial hepatic resection and risk factors of a second HCC recurrence following treatment for the first HCC recurrence.
Results: Using multivariate analysis, a non-sustained virological response (non-SVR) was significantly associated with a high incidence of first HCC recurrence. The rate of second HCC recurrence tended to be higher in the non-SVR group than in the SVR group. In the patients with recurrence of multiple tumors or who received non-curative treatment for recurrent HCC, the second HCC recurrence rates were significantly higher. Multivariate analysis demonstrated that non-curative treatment for first HCC recurrence was an independent risk factor for a second HCC recurrence. Among the patients who received curative treatment for their first HCC recurrence, the rates of second recurrence were significantly higher in the non-SVR group than in the SVR group. Multivariate analysis also revealed that SVR was independently associated with prevention of a second HCC recurrence.
Conclusions: These results suggest that on first HCC recurrence, a curative treatment should be considered in order to prevent a second recurrence if possible. In addition, IFN therapy contributes to improved prognosis after curative treatment, even in patients with recurrent HCC.